An experimental weight-loss drug from Eli Lilly has achieved results in a major clinical trial that rival the effectiveness of bariatric surgery, according to data released by the company. The drug, retatrutide, helped patients lose an average of 28.3 percent of their body weight over 80 weeks at its highest dose.